Helix BioPharma Valuation
| HBP Stock | CAD 2.00 0.05 2.56% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Helix BioPharma Corp retains a regular Real Value of C$1.72 per share. The prevalent price of the firm is C$2.0. Our model calculates the value of Helix BioPharma Corp from evaluating the firm fundamentals such as Shares Owned By Insiders of 28.90 %, return on asset of -0.3, and Return On Equity of -0.66 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Helix BioPharma's valuation include:
Overvalued
Today
Please note that Helix BioPharma's price fluctuation is dangerous at this time. Calculation of the real value of Helix BioPharma Corp is based on 3 months time horizon. Increasing Helix BioPharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Helix BioPharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Helix Stock. However, Helix BioPharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.0 | Real 1.72 | Hype 1.98 | Naive 2.16 |
The intrinsic value of Helix BioPharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Helix BioPharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Helix BioPharma Corp helps investors to forecast how Helix stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Helix BioPharma more accurately as focusing exclusively on Helix BioPharma's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Helix BioPharma's intrinsic value based on its ongoing forecasts of Helix BioPharma's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Helix BioPharma's closest peers.
Helix BioPharma Cash |
|
About Helix BioPharma Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Helix BioPharma Corp. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Helix BioPharma Corp based exclusively on its fundamental and basic technical indicators. By analyzing Helix BioPharma's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Helix BioPharma's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Helix BioPharma. We calculate exposure to Helix BioPharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Helix BioPharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -9 K | -8.6 K | |
| Pretax Profit Margin | (4.70) | (4.94) | |
| Operating Profit Margin | (2.86) | (3.00) | |
| Net Loss | (4.71) | (4.94) | |
| Gross Profit Margin | 0.68 | 0.69 |
Other Information on Investing in Helix Stock
Helix BioPharma financial ratios help investors to determine whether Helix Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Helix with respect to the benefits of owning Helix BioPharma security.